MDMA (3,4-methylenedioxymethamphetamine) is a ring-substituted amphetamine derivative that acts primarily by stimulating the release and inhibiting the reuptake of serotonin, dopamine, and norepinephrine, producing a combined sympathomimetic and serotonergic toxidrome. [1-2] The three most common life-threatening complications requiring ICU admission are threatened airway due to trismus, hyponatremia, and hyperthermia. [3] Mortality in critically ill patients is approximately 4%, with hyperthermia being the strongest predictor of fatal outcomes. [3-4]
1. History
- Substance used, route (usually oral tablet/capsule), dose, timing, and whether "booster" doses were taken — MDMA exhibits nonlinear kinetics, and closely spaced doses produce disproportionate rises in plasma levels [2]
- Setting of use: rave, dance club, festival (crowded, hot, loud environments amplify toxicity) [1]
- Co-ingestants: alcohol, other stimulants, opioids, SSRIs, MAOIs — co-intoxication significantly alters clinical presentation [5]
- Fluid intake: excessive water consumption raises concern for dilutional hyponatremia [6-7]
- Duration and intensity of physical activity (dancing)
- Symptom timeline: euphoria → agitation, jaw clenching, diaphoresis, confusion, seizures
- Prior MDMA use history and any previous adverse reactions
2. Alarm Features
- Hyperthermia ≥40°C (104°F) — rapidly life-threatening; triggers rhabdomyolysis, DIC, hepatic/renal failure, and death [2][8]
- Altered mental status: confusion, obtundation, coma
- Seizures
- Severe trismus with airway compromise or respiratory acidosis [3]
- Signs of serotonin syndrome: clonus (especially lower extremity), hyperreflexia, rigidity, myoclonus, agitation, diaphoresis [9-10]
- Chest pain or signs of acute coronary syndrome (vasospasm-mediated MI can occur even with normal coronaries) [8][11]
- Signs of DIC: petechiae, oozing, bleeding
- Severe hyponatremia with neurological symptoms (Na <130 mEq/L): confusion, seizures, cerebral edema [7][12]
3. Medications
First-line treatments
- Benzodiazepines (midazolam, lorazepam, diazepam) — cornerstone for agitation, seizures, muscle relaxation, and reducing thermogenesis [2][8][13]
- IV crystalloid for volume resuscitation
- Hypertonic saline (3%) for symptomatic hyponatremia with seizures or altered mental status [3][14]
Adjuncts
- Dantrolene — controversial; a meta-analysis suggested improved survival, but a small nonrandomized series showed no difference. Some recommend if core temp >39°C [2][8]
- Cyproheptadine (serotonin antagonist) — may be considered for serotonin syndrome features, though evidence is limited [2]
- Vasodilators (nitrates, CCBs, alpha-blockers) for coronary vasospasm or severe hypertension [8][13]
Contraindicated/Caution
- Antipsychotics — risk of NMS, lowered seizure threshold, hypotension; use with extreme caution [1-2]
- Urine acidification — contraindicated if CK is elevated (promotes renal myoglobin precipitation) [2]
- SSRIs — can worsen serotonin syndrome [2]
- Prolonged physical restraints without effective sedation — associated with death in agitated sympathomimetic-poisoned patients [8][11]
4. Diet
- Fluid restriction is the first-line approach for preventing and treating MDMA-induced hyponatremia (SIAD mechanism) [6]
- Excessive water intake at raves is a major precipitant of fatal hyponatremia — users should be counseled to limit fluid intake to ~500 mL/hour if using MDMA [7]
- No specific dietary triggers; however, dehydration from prolonged dancing in hot environments contributes to hyperthermia and rhabdomyolysis [1]
5. Review of Systems
- Neuro: headache, confusion, agitation, seizures, visual disturbances, bruxism/trismus
- Cardiovascular: palpitations, chest pain, dyspnea
- GI: nausea, vomiting (more common with ethanol co-ingestion), diarrhea, abdominal pain [5]
- Musculoskeletal: muscle rigidity, cramping, dark urine (rhabdomyolysis)
- Psych: anxiety, paranoia, psychosis, hallucinations
- GU: decreased urine output (AKI), dark urine
- Autonomic: diaphoresis, dry mouth, blurred vision
6. Collateral History and Family History
- Friends/bystanders are critical sources — often the only way to confirm substance, dose, timing, and co-ingestants
- Ask about pill appearance, source, and whether others at the event are symptomatic (suggests contaminated batch or high-potency tablets)
- Psychiatric history: prior substance use disorder, depression, anxiety
- Family history is generally less relevant acutely, but CYP2D6 poor metabolizer status (genetic) can increase MDMA plasma levels and toxicity risk [15]
7. Risk Factors
- Environmental: hot, crowded venues; prolonged vigorous dancing; loud noise (aggregation toxicity) [1]
- Female sex: higher incidence and severity of hyponatremia; more vomiting, headache, and hypotension [5][12]
- Polydrug use: co-ingestion with ethanol increases agitation and drowsiness; co-ingestion with other stimulants increases risk of psychosis and coma [5]
- CYP2D6 poor metabolizer phenotype — impaired MDMA metabolism leading to higher plasma levels [15]
- Concurrent serotonergic medications (SSRIs, MAOIs, tramadol) — markedly increases serotonin syndrome risk [16]
- Dose stacking/booster doses due to nonlinear pharmacokinetics [2]
- Excessive fluid intake
8. Differential Diagnosis
- Serotonin syndrome from other serotonergic drugs (SSRIs + MAOIs, tramadol) — distinguished by clonus > rigidity, hyperreflexia, and medication history [10]
- Neuroleptic malignant syndrome — lead-pipe rigidity, bradyreflexia, slower onset (days), antipsychotic exposure
- Anticholinergic toxicity — dry skin (vs. diaphoresis in MDMA), urinary retention, absent bowel sounds, mydriasis
- Sympathomimetic toxicity from cocaine, methamphetamine, bath salts — clinically similar; differentiated by history and urine drug screen [11]
- Heat stroke — exertional or classic; may overlap with MDMA-induced hyperthermia
- Thyroid storm — thyroid history, goiter, exophthalmos
- Meningitis/encephalitis — fever + AMS; check for nuchal rigidity, consider LP
- Intracranial hemorrhage — especially in setting of severe hypertension
- Malignant hyperthermia — perioperative setting, exposure to volatile anesthetics/succinylcholine
9. Past Medical History
- Prior MDMA or stimulant use and adverse reactions
- Psychiatric history (depression, PTSD, anxiety — relevant for concurrent serotonergic medications)
- Cardiovascular disease — increases risk of MI, arrhythmia, cardiomyopathy [17-18]
- Seizure disorder
- Renal or hepatic disease (impaired drug metabolism/clearance)
- Prior episodes of hyponatremia
10. Physical Exam
- Vitals: tachycardia, hypertension, hyperthermia (rectal/core temperature essential), tachypnea
- Neuro: mydriasis, nystagmus, hyperreflexia (especially lower extremities), clonus, tremor, myoclonus, altered mental status [2][19]
- HEENT: bruxism, trismus (jaw clenching — most common reason for ICU admission in one series), dry mucous membranes [3]
- Cardiovascular: tachycardia, murmurs, signs of heart failure
- Skin: diaphoresis, flushing (vs. dry skin in anticholinergic toxicity)
- Abdomen: hyperactive bowel sounds (serotonergic)
- Musculoskeletal: rigidity, muscle tenderness (rhabdomyolysis)
The following figure illustrates the key neuromuscular and autonomic findings in serotonin syndrome, which overlaps significantly with severe MDMA toxicity:
11. Lab Studies
- BMP: sodium (hyponatremia is common — occurred in 31% of subjects after a single dose in controlled trials), potassium, BUN/Cr, glucose, bicarbonate [6]
- CK: rhabdomyolysis screening — levels can exceed 400,000 U/L in severe cases [4]
- CBC with differential
- Hepatic panel: AST/ALT, bilirubin (acute liver injury/failure)
- Coagulation studies: PT/INR, fibrinogen, D-dimer (DIC screening)
- Lactate: marker of tissue hypoperfusion and metabolic stress
- Troponin: if chest pain or ECG changes (MI, myocardial injury)
- Urine drug screen: may detect amphetamines, but false positives and negatives are common [2]
- Urinalysis: myoglobinuria
- ABG/VBG: assess for metabolic/respiratory acidosis [3]
- Serum osmolality: if hyponatremia suspected (confirm SIAD)
12. Imaging
- Chest X-ray: if respiratory distress, aspiration concern, or hypoxia (aspiration pneumonia reported with trismus/sedation) [3]
- CT head without contrast: if seizures, focal neurological deficits, or severe hyponatremia with concern for cerebral edema [7]
- Echocardiography: if signs of heart failure, cardiogenic shock, or suspected takotsubo cardiomyopathy [8][18]
- Imaging is generally not required in mild-moderate toxicity with clear history and improving symptoms
13. Special Tests
- Hunter Serotonin Toxicity Criteria: spontaneous clonus, inducible clonus + agitation/diaphoresis, ocular clonus + agitation/diaphoresis, tremor + hyperreflexia, or temperature >38°C + ocular/inducible clonus — in the setting of a serotonergic agent [10]
- Point-of-care glucose and point-of-care sodium (iSTAT)
- Core temperature via rectal or esophageal probe (axillary/oral unreliable in hyperthermia)
- Urine myoglobin if rhabdomyolysis suspected
- Toxicology confirmation via GC-MS if available (standard immunoassay has limitations) [2]
14. ECG
- Sinus tachycardia — most common finding [2][20]
- Hypertension-related changes: LVH pattern
- QRS prolongation — reported in animal models; may indicate direct cardiotoxicity [21]
- ST-segment changes: elevation or depression suggesting vasospasm-mediated ischemia or MI [8][11]
- Tachyarrhythmias: SVT, VT, VF [22-23]
- Bradyarrhythmias: reported, especially with co-intoxication [5][22]
- QTc prolongation: monitor for risk of torsades
- ECG monitoring is indicated for all patients with significant MDMA toxicity [22]
15. Assessment
MDMA toxicity presents on a spectrum of severity
- Mild: anxiety, tachycardia, mild hypertension, bruxism, mydriasis, diaphoresis — self-limited over 4–6 hours [20]
- Moderate: significant agitation, trismus with airway concern, moderate hyperthermia (<39°C), mild hyponatremia
- Severe: core temperature ≥40°C, seizures, rhabdomyolysis (CK >30,000–100,000 U/L), DIC, acute liver/renal failure, coma, cardiac arrest [2][4]
Patients with temperature <39°C generally do not develop complications of hyperthermia. [3] The combination of hyperpyrexia, altered mental status, DIC, and multiorgan failure carries high mortality. [4] Serotonin syndrome in the setting of MDMA alone is rare; most reported cases involved co-ingestion of other serotonergic agents. [16]
16. Treatment Plan
Initial stabilization (ABCs)
- Airway management — trismus may necessitate intubation; avoid succinylcholine if hyperkalemia/rhabdomyolysis suspected [3]
- Continuous cardiac monitoring and pulse oximetry
Agitation/Seizures
- Benzodiazepines first-line: midazolam 5–10 mg IM/IV, lorazepam 2–4 mg IV, or diazepam 5–10 mg IV; repeat as needed [2][8][13]
- Avoid prolonged physical restraints without chemical sedation [8]
Hyperthermia (core temp ≥40°C)
- Aggressive external cooling: ice water immersion is fastest and preferred; evaporative cooling is an alternative [8]
- Cooling rate >0.15°C/min associated with improved survival [8]
- Benzodiazepines to reduce muscular thermogenesis
- Consider paralysis + intubation if refractory [2]
- Dantrolene — conflicting evidence; may be considered if temp >39°C [2][8]
- Antipyretics (acetaminophen, NSAIDs) are ineffective — hyperthermia is not centrally mediated
Hyponatremia
- Symptomatic (seizures, AMS): 3% hypertonic saline 100–150 mL bolus over 10–20 min; may repeat [3][14]
- Asymptomatic/mild: fluid restriction [6]
- Goal correction: ≤10–12 mEq/L in 24 hours to avoid osmotic demyelination (though overcorrection in one series did not result in reported osmotic demyelination) [3]
Rhabdomyolysis
- Aggressive IV crystalloid resuscitation targeting urine output 200–300 mL/hr
- Monitor CK, renal function, potassium serially [4]
Cardiovascular
- Coronary vasospasm/chest pain: benzodiazepines, nitrates, CCBs; avoid beta-blockers (risk of unopposed alpha stimulation) [8][13]
- Cardiogenic shock/takotsubo: consider ECLS/VA-ECMO as bridge — stress cardiomyopathy often resolves in days to weeks [8]
Serotonin syndrome
- Cyproheptadine 12 mg PO/NG initially, then 4–8 mg q6h
- Benzodiazepines for agitation
- Cooling measures
17. Disposition
ICU admission criteria
- Core temperature ≥39°C with complications (rhabdomyolysis, DIC, organ failure) [3]
- Threatened airway / intubation required
- Symptomatic hyponatremia requiring hypertonic saline
- Hemodynamic instability, arrhythmias, or cardiac arrest
- Refractory agitation or seizures
- Evidence of multiorgan dysfunction
Observation (ED or clinical decision unit)
- Moderate symptoms with improving trajectory
- Mild hyponatremia without neurological symptoms
- Isolated tachycardia/hypertension responding to benzodiazepines
Discharge criteria
- Asymptomatic or mild symptoms that have fully resolved
- Normal mental status, stable vitals for ≥4–6 hours
- Normal sodium, no evidence of rhabdomyolysis
- Reliable follow-up and safe disposition plan
- Poison control consultation as appropriate
Specialist consultation triggers
- Toxicology/Poison Control for all moderate-severe cases
- Nephrology if AKI or severe rhabdomyolysis
- Cardiology if troponin elevation, arrhythmia, or suspected cardiomyopathy
- Surgery/critical care if DIC or hepatic failure
18. Follow Up / Return Precautions
- Return immediately for: recurrent confusion, seizures, dark urine, chest pain, persistent vomiting, inability to tolerate fluids, fever
- Recheck sodium in 24–48 hours if hyponatremia was present
- Monitor renal function and CK if rhabdomyolysis was identified
- Counsel on risks of MDMA use, including unpredictable dose-response, nonlinear kinetics, and risk of long-term serotonergic neurotoxicity [1-2]
- Substance use disorder screening and referral to addiction services
- Psychiatric follow-up if concurrent mental health concerns
- Expected recovery: majority of patients with appropriate management make a full recovery; however, "midweek blues" (depressed mood 2–5 days post-use due to serotonin depletion) are reported in 80–90% of users [3][24]
References
1. Review of the Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy"). — Green AR, Cross AJ, Goodwin GM. Psychopharmacology. 1995.
2. Recognition and Management of Complications of New Recreational Drug Use. — Ricaurte GA, McCann UD. Lancet. 2005.
3. Acute Complications and Treatment in Critically Ill Patients With 3,4-Methylenedioxymetamfetamine Intoxication: A 10-Year Retrospective Observational Study in an Intensive Care Unit in an Amsterdam Hospital. — Zuidema MJ, Reimerink E, Akhoundzadeh D, van den Bogaard B, Gresnigt FMJ. Clinical Toxicology. 2025.
4. Protracted Hyperthermia and Delayed Rhabdomyolysis in Ecstasy Toxicity: A Case Report. — Ghaffari-Rafi A, Eum KS, Villanueva J, Jahanmir J. Medicine. 2020.
5. Differences in the Clinical Presentation of Acute 3,4-Methylenedioxymetamfetamine Intoxication by Co-Intoxication and Patient Sex to European Emergency Departments. — Ouwerkerk JJJ, Wood DM, Dines AM, et al. Clinical Toxicology. 2025.
6. Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials. — Atila C, Straumann I, Vizeli P, et al. JAMA Network Open. 2024.
7. Drinking to Death: Hyponatraemia Induced by Synthetic Phenethylamines. — Faria AC, Carmo H, Carvalho F, et al. Drug and Alcohol Dependence. 2020.
8. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
9. Serotonin Syndrome. — Bodner RA, Lynch T, Lewis L, Kahn D. Neurology. 1995.
10. Serotonin Syndrome-a Focused Review. — Mikkelsen N, Damkier P, Pedersen SA. Basic & Clinical Pharmacology & Toxicology. 2023.
11. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation. 2023.
12. Rare but Relevant: MDMA and Hyponatraemia. — Garcia MR, Gomes NGM, Dias-da-Silva D. Addiction. 2025.
13. Treatment of Toxicity From Amphetamines, Related Derivatives, and Analogues: A Systematic Clinical Review. — Richards JR, Albertson TE, Derlet RW, et al. Drug and Alcohol Dependence. 2015.
14. Management of Stimulant Use Disorder. — Steven Batki MD, Daniel Ciccarone MD MPH, Scott E. Hadland MD MPH, et al American Academy of Addiction Psychiatry (2023). 2023.
15. Pharmacokinetics and Pharmacodynamics of 3,4-Methylenedioxymethamphetamine (MDMA): Interindividual Differences Due to Polymorphisms and Drug-Drug Interactions. — Rietjens SJ, Hondebrink L, Westerink RH, Meulenbelt J. Critical Reviews in Toxicology. 2012.
16. Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database. — Makunts T, Jerome L, Abagyan R, de Boer A. Frontiers in Psychiatry. 2022.
17. Ecstasy (3,4-Methylenedioxymethamphetamine): Cardiovascular Effects and Mechanisms. — Fonseca DA, Ribeiro DM, Tapadas M, Cotrim MD. European Journal of Pharmacology. 2021.
18. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. — Bozkurt B, Colvin M, Cook J, et al. Circulation. 2016.
19. The Serotonin Syndrome. — Boyer EW, Shannon M. The New England Journal of Medicine. 2005.
20. Safety Pharmacology of Acute MDMA Administration in Healthy Subjects. — Vizeli P, Liechti ME. Journal of Psychopharmacology. 2017.
21. Roles of 3,4-Methylenedioxymethamphetamine (MDMA)-induced Alteration of Connexin43 and Intracellular Ca(2+) Oscillation in Its Cardiotoxicity. — Zhuo L, Liu Q, Liu L, et al. Toxicology. 2013.
22. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. — Sandau KE, Funk M, Auerbach A, et al. Circulation. 2017.
23. The Cardiovascular and Cardiac Actions of Ecstasy and Its Metabolites. — Shenouda SK, Carvalho F, Varner KJ. Current Pharmaceutical Biotechnology. 2010.
24. Recreational Ecstasy/Mdma, the Serotonin Syndrome, and Serotonergic Neurotoxicity. — Parrott AC. Pharmacology, Biochemistry, and Behavior. 2002.